Intracerebral Hemorrhage — Acute Management

Key Points

• Obtain noncontrast head CT immediately and repeat imaging when clinical change or expansion risk warrants it.
• Reverse anticoagulant effect rapidly using the appropriate agent and time-of-last-dose information.
• In many mild to moderate ICH patients with presenting SBP 150 to 220 mm Hg, target smooth lowering toward 140 and maintain roughly 130 to 150.
• Avoid overshooting systolic pressure below 130 mm Hg in the usual mild to moderate acute ICH population.
• Do not routinely transfuse platelets for aspirin-associated spontaneous ICH when emergency neurosurgery is not planned.
• Treat seizures when they occur; routine prophylactic antiseizure therapy is not recommended for all patients.
• Hydrocephalus with reduced consciousness requires urgent ventricular drainage assessment.
• Severity scores support communication but should not be the sole basis for limiting life-sustaining treatment early.

Algorithm

1. Stabilize airway and circulation, check glucose, and obtain immediate noncontrast head CT.
2. Confirm ICH, assess volume/location, intraventricular hemorrhage, hydrocephalus, mass effect, and need for CTA or other vascular imaging.
3. Identify anticoagulant or antiplatelet exposure and reverse clinically significant anticoagulant effect immediately.
4. Start smooth IV blood-pressure control when indicated while avoiding hypotension and excessive variability.
5. Admit to a stroke or neurocritical-care setting and perform frequent neurologic examinations.
6. Consult neurosurgery urgently for cerebellar hemorrhage, hydrocephalus, mass effect, deterioration, or another potentially operable lesion.
7. Repeat CT according to clinical course and manage fever, glucose, seizures, VTE risk, nutrition, and swallowing.
8. After stabilization, investigate hemorrhage mechanism and begin secondary prevention, rehabilitation, and blood-pressure management.

Clinical Synopsis & Reasoning

ICH often presents with abrupt focal neurologic deficit, headache, vomiting, seizure, depressed consciousness, or rapid neurologic decline. Obtain noncontrast head CT immediately to define location and volume, intraventricular extension, hydrocephalus, and mass effect. CTA can identify a macrovascular cause or spot sign in selected patients, especially younger patients or hemorrhage in an atypical location. Assess use of warfarin, factor Xa inhibitors, dabigatran, heparin, antiplatelet therapy, and the timing of the last dose. Serial neurologic examination and repeat imaging detect hematoma expansion, hydrocephalus, and herniation. Common causes include hypertensive arteriopathy, cerebral amyloid angiopathy, anticoagulation, vascular malformation, tumor, and sympathomimetic exposure. In mild to moderate ICH presenting with systolic pressure 150 to 220 mm Hg, carefully titrated reduction toward about 140 mm Hg with maintenance in the 130 to 150 range is generally safe; pushing below 130 mm Hg can be harmful. Blood-pressure goals differ in massive hemorrhage, impending herniation, or when cerebral perfusion is threatened. Check glucose, temperature, sodium, coagulation status, platelets, renal function, and cardiac rhythm because systemic derangements worsen neurologic injury.

Treatment Strategy & Disposition

Stop anticoagulants and reverse promptly when clinically significant drug effect is present. Warfarin-associated ICH is treated with four-factor prothrombin complex concentrate plus intravenous vitamin K. Dabigatran can be reversed with idarucizumab. Factor Xa inhibitor-associated life-threatening ICH can be treated with andexanet alfa where appropriate or four-factor PCC when a specific antidote is unavailable or unsuitable, following institutional protocols. Routine platelet transfusion for aspirin-associated spontaneous ICH without emergency neurosurgery is not beneficial and can be harmful. Use titratable IV antihypertensive therapy such as nicardipine or clevidipine to achieve smooth control without large variability. Treat clinical seizures, but do not give routine prophylactic antiseizure medication to every patient. External ventricular drainage is indicated for hydrocephalus causing reduced consciousness. Emergency surgery is clearly indicated for selected cerebellar hemorrhage with neurologic deterioration, brainstem compression, obstructive hydrocephalus, or large volume, while supratentorial evacuation is individualized. Provide mechanical VTE prophylaxis early; low-dose pharmacologic prophylaxis can be considered after hematoma stability according to timing and bleeding risk.

Epidemiology / Risk Factors

• ICH accounts for a minority of strokes but a disproportionate share of stroke mortality.
• Chronic hypertension is a major cause, particularly for deep basal ganglia, thalamic, pontine, and cerebellar hemorrhage.
• Cerebral amyloid angiopathy is an important cause of lobar hemorrhage in older adults.
• Use of anticoagulants increases ICH risk and makes rapid reversal a key emergency intervention.
• Early hematoma expansion is common enough that the first hours are a major therapeutic window.

Investigations

Common Reversal Strategies

Pharmacology

Prognosis / Complications

• Early mortality is high and is strongly associated with hematoma size, location, intraventricular extension, age, level of consciousness, and medical complications.
• Meaningful recovery can continue for months, so early neurologic severity does not define the final functional outcome.
• Recurrent hemorrhage risk depends on etiology, blood-pressure control, amyloid angiopathy, antithrombotic exposure, and vascular lesions.
• Dysphagia, aspiration, VTE, infection, delirium, depression, and immobility complications influence outcome and require active prevention.
• Caregiver training and coordinated rehabilitation are important parts of long-term recovery.

Patient Education / Counseling

• Explain the hemorrhage location, likely cause, current neurologic risks, and why repeat imaging or intensive monitoring is necessary.
• Discuss uncertainty in early prognosis and avoid implying that a severity score alone predicts an individual's ultimate recovery.
• For survivors, emphasize strict long-term blood-pressure control and adherence to follow-up imaging or vascular evaluation when indicated.
• Review any future antiplatelet or anticoagulant decision with neurology and the clinician managing the competing thrombotic indication.
• Advise urgent emergency evaluation for new focal weakness, speech change, severe headache, seizure, or loss of consciousness.

Notes

ICH care is built around preventing secondary injury during the first hours while avoiding interventions that add harm. Rapid imaging, anticoagulant reversal, controlled blood-pressure reduction, hydrocephalus treatment, and selective surgery have clear roles. Routine platelet transfusion, routine seizure prophylaxis, and premature prognostic withdrawal do not. After the acute phase, the work continues with etiologic evaluation, rehabilitation, dysphagia and VTE prevention, and aggressive long-term blood-pressure management to reduce recurrence.

References

1. 2022 AHA/ASA Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage — Link